Consensus guidelines for the use of empiric and diagnostic‐driven antifungal treatment strategies in haematological malignancy, 2014
Open Access
- 8 December 2014
- journal article
- review article
- Published by Wiley in Internal Medicine Journal
- Vol. 44 (12b), 1298-1314
- https://doi.org/10.1111/imj.12596
Abstract
Invasive fungal disease (IFD) causes significant morbidity and mortality in patients undergoing allogeneic haemopoietic stem cell transplantation or chemotherapy for haematological malignancy. Much of these adverse outcomes are due to the limited ability of traditional diagnostic tests (i.e. culture and histology) to make an early and accurate diagnosis. As persistent or recurrent fevers of unknown origin (PFUO) in neutropenic patients despite broad‐spectrum antibiotics have been associated with the development of IFD, most centres have traditionally administered empiric antifungal therapy (EAFT) to patients with PFUO. However, use of an EAFT strategy has not been shown to have an overall survival benefit and is associated with excessive antifungal therapy use. As a result, the focus has shifted to developing more sensitive and specific diagnostic tests for early and more targeted antifungal treatment. These tests, including the galactomannan enzyme‐linked immunosorbent assay and Aspergillus polymerase chain reaction (PCR), have enabled the development of diagnostic‐driven antifungal treatment (DDAT) strategies, which have been shown to be safe and feasible, reducing antifungal usage. In addition, the development of effective antifungal prophylactic strategies has changed the landscape in terms of the incidence and types of IFD that clinicians have encountered. In this review, we examine the current role of EAFT and provide up‐to‐date data on the newer diagnostic tests and algorithms available for use in EAFT and DDAT strategies, within the context of patient risk and type of antifungal prophylaxis used.Keywords
This publication has 90 references indexed in Scilit:
- Evaluation of Real-Time PCR, Galactomannan Enzyme-Linked Immunosorbent Assay (ELISA), and a Novel Lateral-Flow Device for Diagnosis of Invasive AspergillosisJournal of Clinical Microbiology, 2013
- Diagnostic Performance of an Aspergillus-Specific Nested PCR Assay in Cerebrospinal Fluid Samples of Immunocompromised Patients for Detection of Central Nervous System AspergillosisPLOS ONE, 2013
- Systematic Review and Meta-Analysis of Detecting Galactomannan in Bronchoalveolar Lavage Fluid for Diagnosing Invasive AspergillosisPLOS ONE, 2012
- Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samplesEuropean Journal of Haematology, 2012
- Galactomannan Antigen Testing for Diagnosis of Invasive Aspergillosis in Pediatric Hematology PatientsJournal of the Pediatric Infectious Diseases Society, 2012
- Evaluation of PCR on Bronchoalveolar Lavage Fluid for Diagnosis of Invasive Aspergillosis: A Bivariate Metaanalysis and Systematic ReviewPLOS ONE, 2011
- Diagnosis of Invasive Aspergillosis by a Commercial Real-Time PCR Assay for Aspergillus DNA in Bronchoalveolar Lavage Fluid Samples from High-Risk Patients Compared to a Galactomannan Enzyme ImmunoassayJournal of Clinical Microbiology, 2011
- Critical Stages of Extracting DNA from Aspergillus fumigatus in Whole-Blood SpecimensJournal of Clinical Microbiology, 2010
- Aspergillus PCR: One Step Closer to StandardizationJournal of Clinical Microbiology, 2010
- Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus GroupClinical Infectious Diseases, 2008